NCT02132598View on ClinicalTrials.gov

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 9, 2019

Study Completion Date

August 9, 2019

Conditions

Non Small Cell Lung Cancer (NSCLC)Metastases to the Brain

Interventions

DRUG

cabozantinib

Trial Locations (1)

15232

University of Pittsburgh Cancer Institute- Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Exelixis

INDUSTRY

lead

Liza Villaruz, MD

OTHER